In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Elevated levels of 2-arachidonoylglycerol promote atherogenesis and hamper endothelial repair in murine models
Authors : J Jehle (Bonn,DE), B Schoene (Bonn,DE), S Bagheri (Bonn,DE), I Frank (Bonn,DE), P Pfeifer (Bonn,DE), L Bindila (Mainz,DE), B Lutz (Mainz,DE), D Luetjohann (Bonn,DE), A Kraemer (Bonn,DE), A Zimmer (Bonn,DE), G Nickenig (Bonn,DE)
J. Jehle1
,
B. Schoene1
,
S. Bagheri1
,
I. Frank1
,
P. Pfeifer1
,
L. Bindila2
,
B. Lutz2
,
D. Luetjohann3
,
A. Kraemer3
,
A. Zimmer3
,
G. Nickenig1
,
1University Hospital Bonn, Department of Cardiology - Bonn - Germany
,
2Johannes Gutenberg University Mainz (JGU) - Mainz - Germany
,
3University Hospital Bonn - Bonn - Germany
,
Background: The endocannabinoid (eCB) 2-arachidonoylglycerol (2-AG) is a known modulator of inflammation and ligand to both, pro-inflammatory cannabinoid receptor 1 (CB1) and anti-inflammatory CB2. While both receptors have been studied extensively, the role of 2-AG in atherogenesis and endothelial repair is less well characterised.
Methods: The impact of 2-AG on atherogenesis was studied in two treatment groups of ApoE−/− mice. One group received the monoacylglycerol lipase (MAGL)-inhibitor JZL184 [5 mg/kg i.p.], which impairs 2-AG degradation and thus causes elevated 2-AG levels, the other group received vehicle for four weeks. Simultaneously, both groups were fed a high-cholesterol diet. The atherosclerotic plaque burden was assessed in frozen sections through the aortic sinus following oil red O staining and infiltrating macrophages were detected by immunofluorescence targeting CD68. In vitro, the effect of 2-AG on B6-MCL macrophage migration was assessed by Boyden chamber experiments. Finally, endothelial repair was studied in wildtype mice receiving either JZL184 [5 mg/kg i.p.] or vehicle following electrical denudation of the common carotid artery.
Results: As expected, application of the MAGL-inhibitor JZL184 resulted in a significant increase in 2-AG levels in vascular tissue (98.2±16.1 nmol/g vs. 27.3±4.5 nmol/g; n=14–16; p<0.001). ApoE−/− mice treated with JZL184 displayed a significantly increased plaque burden compared to vehicle treated controls (0.46±0.03 vs. 0.36±0.03; n=11–12; p<0.05). This was accompanied by a significant increase in infiltrating macrophages within the atherosclerotic vessel wall (0.32±0.02 vs. 0.26±0.01; n=11; p<0.05). Consistently, 2-AG enhanced macrophage migration in vitro by 1.7±0.2 -fold (n=4; p<0.05) compared to vehicle, which was completely abolished by co-administration of the CB1-receptor-antagonist AM281. Finally, elevated 2-AG levels significantly impaired reendothelialisation in wildtype mice following electrical injury of the common carotid artery, resulting in a residual denudation at 5 days of 2291±286 μm vs. 1505±223 μm (n=18–19; p<0.05).
Conclusion: Taken together, elevated 2-AG levels appear to hamper endothelial repair and to promote atherogenesis in vivo. Our data suggest that 2-AG promotes macrophage migration via a CB1-dpendent pathway and thereby potentially contributes to vascular inflammation. Thus, decreasing vascular 2-AG levels might represent a promising therapeutic strategy in patients suffering from atherosclerosis and coronary heart disease.
